Alliance Presents Results from Phase III ATOMIC Trial Combining Atezolizumab with Chemotherapy for Patients with Stage III dMMR Colon Cancer at ASCO 2025

The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, de


UPCOMING MEETINGS

Spring Group Meetings
- May 13-15, 2026

Fall Group Meetings
- November 5-7, 2025
- November 4-6, 2026

All meetings will be held at the Loews Chicago O'Hare Hotel in Rosemont, IL and are open to all
Alliance members.
 

ALLIANCE ON SOCIAL

FROM THE NCI